Novel MmpL3 inhibitor

(E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.

Novel CCR4 antagonist, enhancing DC activation and homing to the regional lymph node and showing potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment

Novel dual FLT3/Aurora A inhibitor, overcoming D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells

Inactive analogue of pictilisib to be used as the negative control

Highly Selective Oral Checkpoint Kinase 1 (CHK1) Inhibitor

Novel inhibitor of BCL6

Novel inhibitor of the efflux function of ABCG2, selectively reversing ABCG2-mediated MDR in cancer cells in vitro and in vivo

Novel potent covalent BRD4 degrader, degrading BRD4 in a proteasome- and RNF4-dependent manner without inhibiting RNF4 autoubiquitination activity

Novel MC1R agonist

Novel Caspase-1 inhibitor

Novel telomerase inhibitor

Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA

Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel selective cdDHQD inhibitor

Novel potent and selective CDK12 inhibitor

Potent, ATP-binding site-targeting Cdk4/D1 inhibitor

Novel potent CDK6 degrader